<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Male pattern hair loss (androgenetic alopecia in males): Pathogenesis, clinical features, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Male pattern hair loss (androgenetic alopecia in males): Pathogenesis, clinical features, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Male pattern hair loss (androgenetic alopecia in males): Pathogenesis, clinical features, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeff Donovan, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Beth G Goldstein, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adam O Goldstein, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maria Hordinsky, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 04, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H21714513"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Male pattern hair loss (MPHL) is the most common type of hair loss in males. The condition is characterized by the progressive loss of terminal hairs on the scalp in a characteristic distribution. The anterior scalp, mid-scalp, temporal scalp, and vertex of the scalp are typical sites of involvement  (<a class="graphic graphic_picture graphicRef83802 graphicRef83804 graphicRef120282 graphicRef83805" href="/z/d/graphic/83802.html" rel="external">picture 1A-D</a>). "Male balding" and "male pattern hair loss" are additional terms used to refer to this condition.</p><p>The pathogenesis, clinical features, and diagnosis of MPHL will be reviewed here. The treatment of MPHL in males, female pattern hair loss (androgenetic alopecia in females), and the general approach to the evaluation and diagnosis of hair loss are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3321.html" rel="external">"Male pattern hair loss (androgenetic alopecia in males): Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15679.html" rel="external">"Female pattern hair loss (androgenetic alopecia in females): Pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/86648.html" rel="external">"Female pattern hair loss (androgenetic alopecia in females): Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss"</a>.)</p><p></p><p class="headingAnchor" id="H21714527"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>MPHL is a common postpubertal disorder that occurs worldwide and exhibits increasing prevalence with age. Prevalence estimates from studies in different countries suggest differences in prevalence based upon race or ethnicity; however, wide variation in study methods have made comparisons of prevalence estimates difficult [<a href="#rid1">1-7</a>].</p><p>For example, a study in the United States found at least moderate androgenetic alopecia (Hamilton-Norwood III or above  (<a class="graphic graphic_figure graphicRef86709" href="/z/d/graphic/86709.html" rel="external">figure 1</a>)) in 48 percent of 266 healthy males (ages 18 to 49 years), including 16 percent of males between the ages of 18 and 29 years and 53 percent of males between the ages of 40 and 49 years [<a href="#rid6">6</a>]. Prevalences appeared to be lower in a Korean study that involved examination of males visiting a hospital for regular health examinations. The Korean study found MPHL (Hamilton-Norwood III or above) in only 14 percent of 5531 males (ages 20 and older), increasing from 2 percent among individuals aged 20 to 29 years to 11 percent among individuals aged 40 to 49 years [<a href="#rid1">1</a>].</p><p>The prevalence of MPHL in the pediatric population (children and adolescents under 18) is not well studied. However, it is slowly being recognized that both childhood-onset androgenetic alopecia (age 6 to 11) and adolescent-onset androgenetic alopecia are both distinct pediatric entities [<a href="#rid8">8-10</a>].</p><p class="headingAnchor" id="H21714534"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>MPHL is considered an androgen-dependent trait that requires a genetic predisposition. The interaction of these factors and other mechanisms that remain to be elucidated contributes to follicular miniaturization (the transition of larger, terminal hair fibers to small vellus hair fibers) in susceptible scalp areas. (See <a class="local">'Androgens'</a> below and <a class="local">'Genetics'</a> below and <a class="local">'Follicular miniaturization'</a> below and <a class="local">'Other factors'</a> below.)</p><p class="headingAnchor" id="H21714541"><span class="h2">Androgens</span><span class="headingEndMark"> — </span>Consistent with a critical role for androgens, MPHL typically develops after puberty, a phase associated with a dramatic increase in androgen production. In addition, males with androgen insensitivity syndrome do not develop the condition [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/7458.html" rel="external">"Pathogenesis and clinical features of disorders of androgen action", section on 'Complete androgen insensitivity (CAIS)'</a>.)</p><p>Dihydrotestosterone (DHT) is the key androgen involved in the induction and promotion of MPHL [<a href="#rid12">12</a>]. DHT is a potent metabolite of testosterone and, compared with testosterone, has greater affinity for the androgen receptor.</p><p>The 5-alpha reductase enzyme mediates the conversion of testosterone to DHT and exists in two isoforms in scalp hair follicles: type 1 and type 2. Although both isoforms have a role in MPHL, the role of the type 2 isoform is greater. The type 2 isoform is located in the outer root sheath of hair follicles as well as the epididymis, vas deferens, seminal vesicles, and prostate. The type 1 isoform is located in sebaceous glands, epidermal and follicular keratinocytes, dermal papillae cells, and sweat glands.</p><p>The importance of 5-alpha reductase is supported by the absence of MPHL in males with mutations in the 5-alpha reductase type 2 gene [<a href="#rid13">13</a>]. In addition, inhibitors of 5-alpha reductase (eg, <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a>, <a class="drug drug_general" data-topicid="8672" href="/z/d/drug information/8672.html" rel="external">dutasteride</a>) are effective therapies for MPHL. (See  <a class="medical medical_review" href="/z/d/html/7470.html" rel="external">"Steroid 5-alpha-reductase 2 deficiency"</a> and  <a class="medical medical_review" href="/z/d/html/3321.html" rel="external">"Male pattern hair loss (androgenetic alopecia in males): Management"</a>.)</p><p>Intrinsic differences in hormone metabolism and hormone receptors may also contribute to MPHL. Young adult males with MPHL have higher levels of cellular 5-alpha reductase and a higher quantity of androgen receptors in the balding scalp than in the nonbalding scalp [<a href="#rid14">14</a>]. In addition, production rates of DHT are higher in males with MPHL than in males without the condition [<a href="#rid15">15</a>]. Although plasma testosterone concentrations are similar in balding and nonbalding males [<a href="#rid16">16</a>], elevated levels of unbound testosterone (the active fraction of testosterone) have been detected in some patients with MPHL [<a href="#rid17">17,18</a>].</p><p>Additional study is necessary to clarify the effects of exogenous androgens (anabolic steroids, testosterone supplementation) on the progression of MPHL. Progression of androgenetic alopecia has been observed in transgender males (assigned female at birth) prescribed gender-affirming hormone therapy with testosterone [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H21714548"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>MPHL is considered a heritable disorder [<a href="#rid20">20</a>], a concept supported by the results of familial studies [<a href="#rid21">21-23</a>]. A study of 572 males (ages 16 to 91 years) evaluated in a dermatology clinic for concerns unrelated to MPHL found that participants under 30 years of age with a balding father were more than five times more likely to have MPHL than similarly aged participants with fathers without the condition (relative risk 5.5, 95% CI 1.26-23.99) [<a href="#rid22">22</a>]. In addition, a study of approximately 500 monozygotic male twins and 400 dizygotic male twins between the ages of 25 and 36 attributed 80 percent of the variance in the extent of hair loss to genetic effects [<a href="#rid23">23</a>].</p><p>Multiple genetic susceptibility loci for MPHL have been identified [<a href="#rid24">24,25</a>]. Examples include the androgen receptor (AR)/EDAR2 locus on the X chromosome [<a href="#rid26">26</a>], the PAX1/FOXA2 locus on chromosome 20p11 [<a href="#rid27">27,28</a>], and <em>HDAC9</em> gene on chromosome 7p21.1 [<a href="#rid20">20,29</a>]. Chromosome 3q26 may also have a contributory role [<a href="#rid30">30</a>]. Many other loci continue to be uncovered [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H904719274"><span class="h2">Follicular miniaturization</span><span class="headingEndMark"> — </span>The perception of hair "loss" in MPHL results from shortening of the anagen (growth) phase of hair follicles rather than the complete cessation of hair growth in affected areas [<a href="#rid32">32</a>]. The shortened anagen phase leads to the production of shorter, thinner vellus hair shafts, a process called follicular miniaturization  (<a class="graphic graphic_picture graphicRef83781" href="/z/d/graphic/83781.html" rel="external">picture 2</a>). As additional follicles undergo miniaturization, hair coverage of the scalp progressively decreases. (See  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Hair biology'</a>.)</p><p>Follicular miniaturization is caused by a hormonally mediated process at the level of the hair follicle dermal papilla [<a href="#rid33">33</a>]. At the cellular level, DHT binds to the androgen receptor, and the hormone-receptor complex then activates the genes responsible for the gradual transformation of large, terminal follicles to smaller follicles with a shortened anagen phase [<a href="#rid34">34-37</a>]. The precise mechanisms through which genetic variants contribute to the induction of follicular miniaturization remain unclear [<a href="#rid38">38</a>]. (See <a class="local">'Genetics'</a> above.)</p><p>The gradual transformation is associated with apoptosis of cells within the dermal papilla and a reduction in the overall size of the dermal papilla. This may be central to the miniaturization process given that the size of the dermal papilla correlates well with the caliber of the hair fiber produced.</p><p class="headingAnchor" id="H320237176"><span class="h2">Other factors</span><span class="headingEndMark"> — </span>Although hormone-mediated pathogenic mechanisms have been an intensive focus of research, a variety of other pathogenic mechanisms may be relevant. These include Wnt signals, prostaglandin D2 signals, prostaglandin F2-alpha signals, and Janus kinase (JAK) signals, among others [<a href="#rid39">39,40</a>]. New treatments for androgenetic alopecia based upon targeting of these mechanisms are under investigation [<a href="#rid41">41,42</a>].</p><p class="headingAnchor" id="H21714555"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>MPHL is characterized by varying degrees of hair follicle miniaturization and reduction in terminal hair density on the scalp in characteristic locations  (<a class="graphic graphic_picture graphicRef83802 graphicRef83804 graphicRef120282 graphicRef83805" href="/z/d/graphic/83802.html" rel="external">picture 1A-D</a>). The degree of scalp involvement may change over time as the condition progresses.</p><p>Some patients with MPHL may occasionally report symptoms such as itching, but it remains to be fully elucidated as to whether these symptoms are a bona fide feature of androgenetic alopecia and whether such symptoms correlate with the histologic findings of perifollicular inflammation that are known to characterize this hair loss condition. (See <a class="local">'Histopathology'</a> below.)</p><p>Many patients with MPHL who present with concerns about itching have identifiable reasons separate from the MPHL itself, such as seborrheic dermatitis. Whether MPHL itself has a symptomatic phase awaits further study.</p><p class="headingAnchor" id="H1746535364"><span class="h2">Pattern and course</span><span class="headingEndMark"> — </span>Signs of MPHL may first appear during adolescence. Terminal hair loss typically begins in the temporal scalp, midfrontal scalp, or vertex area of the scalp  (<a class="graphic graphic_picture graphicRef83802 graphicRef83804 graphicRef120282 graphicRef83805" href="/z/d/graphic/83802.html" rel="external">picture 1A-D</a>). The severity of involvement of these areas is highly variable; in some males, the greatest degree of hair loss occurs at the vertex, and other affected individuals exhibit the most severe hair loss anteriorly. (See  <a class="medical medical_review" href="/z/d/html/3321.html" rel="external">"Male pattern hair loss (androgenetic alopecia in males): Management", section on 'Hair transplantation'</a>.)</p><p>MPHL is a continuous process that progresses slowly over the course of many years. The two most common patterns for progression of hair loss are reviewed in this figure  (<a class="graphic graphic_figure graphicRef86709" href="/z/d/graphic/86709.html" rel="external">figure 1</a>). Hair loss occurs in waves of activity, with more rapid intervals of hair loss at certain times followed by periods of minimal activity.</p><p>Childhood-onset or adolescent-onset androgenetic alopecia appears to favor the vertex areas, with a tendency to spare the frontal hairline and temples during early progression [<a href="#rid8">8-10</a>].</p><p class="headingAnchor" id="H2312129957"><span class="h2">Classification</span><span class="headingEndMark"> — </span>The Hamilton-Norwood scale is commonly used to classify MPHL although other systems are also used [<a href="#rid43">43</a>]. The Hamilton-Norwood scale divides the clinical findings into seven stages and offers a visual depiction of the sequential stages of balding  (<a class="graphic graphic_figure graphicRef86709" href="/z/d/graphic/86709.html" rel="external">figure 1</a>). The scale also describes a less common type A variant of hair loss in which men demonstrate only the progressive movement of the anterior hairline posteriorly  (<a class="graphic graphic_figure graphicRef86709" href="/z/d/graphic/86709.html" rel="external">figure 1</a>) [<a href="#rid44">44</a>].</p><p>Not all individuals with MPHL follow the hair loss patterns outlined by the Hamilton-Norwood scale. For example, 10 percent of affected males have a pattern that resembles female pattern hair loss (preservation of the frontal hairline and terminal hair loss in the central scalp)  (<a class="graphic graphic_picture graphicRef120665" href="/z/d/graphic/120665.html" rel="external">picture 3</a>) [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/z/d/html/15679.html" rel="external">"Female pattern hair loss (androgenetic alopecia in females): Pathogenesis, clinical features, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H3483790254"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>The histopathologic findings in MPHL and female pattern hair loss (FPHL) are similar. The characteristic findings can be identified on scalp specimens sectioned horizontally or vertically.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Horizontal sections </strong>– The histologic features are more readily seen in horizontal sections. Depending on the severity of the clinical findings, there is a variable mixture of terminal, vellus, and vellus-like hair follicles in the dermis. The vellus and vellus-like hairs are &lt;0.03 mm in diameter [<a href="#rid46">46</a>]. Terminal hairs (&gt;0.06 mm) are seen in the reticular dermis.</p><p></p><p class="bulletIndent1">The ratios of anagen to telogen (A:T) hair follicles and terminal to vellus (T:V) hair follicles are altered and can be readily evaluated with horizontal sections. The A:T ratio progressively falls from 12:1 to less than 5:1. The T:V ratio is progressively reduced as miniaturization progresses [<a href="#rid47">47</a>]. For example, with further progression of the condition, the T:V ratio may slowly approach 1:1, and then the ratio is reversed, with T:V ratios of 1:2 or less and conversion from terminal to vellus hairs becomes complete. These alterations in the T:V ratio can be extremely helpful in the diagnosis of MPHL or FPHL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vertical sections </strong>– Vertical sections show terminal hair follicles rooted in the subcutaneous and reticular dermis and vellus hair follicles located more superficially in the papillary dermis. Vertical columns of connective tissue, known as follicular stelae or follicular streamers, can be seen [<a href="#rid48">48,49</a>]. The follicular stelae that originate in the deep dermis and underlie vellus hairs in the more superficial dermis may represent connective tissue that previously surrounded terminal hair follicles prior to miniaturization [<a href="#rid47">47</a>].</p><p></p><p>Inflammation is not uncommon in histologic specimens of MPHL and FPHL despite the fact that these conditions have traditionally been classified as noninflammatory forms of hair loss [<a href="#rid50">50,51</a>]. In one retrospective study that included 53 female and 5 male patients with FPHL or MPHL, perifollicular inflammation was found in 88 percent of biopsies [<a href="#rid50">50</a>]. Inflammation was found in the isthmus and infundibulum, although the inflammation at the level of the isthmus was more common. Inflammation was typically mild, although moderate and severe inflammation at the level of the isthmus was not uncommon.</p><p>The inflammation in MPHL and FPHL differs significantly from the intense peribulbar inflammation that is typically found in alopecia areata. The precise role of the inflammatory response seems unclear, although its presence early in the course of MPHL and FPHL and around miniaturized hairs has led some authors to postulate it may contribute to miniaturization, perifollicular fibrosis [<a href="#rid52">52</a>], and fibrosis [<a href="#rid53">53</a>].</p><p>Mild, perifollicular fibrosis is an additional feature that may be detected [<a href="#rid48">48</a>]. Although perifollicular fibrosis as well as peri-isthmal/infundibular inflammation can be seen in scarring alopecias, such as lichen planopilaris, the scarring alopecias typically show loss/reduction of sebaceous glands and often lichenoid-type changes in the outer root sheath that are not present in MPHL [<a href="#rid54">54</a>].</p><p>The presence of inflammation or fibrosis may have prognostic significance. In a study of patients with MPHL treated with topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a>, 55 percent of 22 subjects with inflammation or fibrosis responded to minoxidil compared with 77 percent of 22 subjects without histopathologic evidence for inflammation or fibrosis [<a href="#rid48">48</a>]. Further studies are necessary to confirm this finding.</p><p class="headingAnchor" id="H3907932529"><span class="h1">ASSOCIATED DISORDERS</span><span class="headingEndMark"> — </span>MPHL may have negative psychosocial effects and has been linked to other disorders, such as cardiovascular disease and prostate cancer. </p><p class="headingAnchor" id="H3697399544"><span class="h2">Psychosocial effects</span><span class="headingEndMark"> — </span>The psychosocial impact of MPHL varies. Patients with MPHL may experience stress and psychologic distress related to hair loss, reduced quality of life, and infrequently, related body dysmorphic disorder [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/z/d/html/15679.html" rel="external">"Female pattern hair loss (androgenetic alopecia in females): Pathogenesis, clinical features, and diagnosis", section on 'Psychosocial dysfunction'</a> and  <a class="medical medical_review" href="/z/d/html/14825.html" rel="external">"Body dysmorphic disorder: Clinical features"</a>.)</p><p class="headingAnchor" id="H2248611112"><span class="h2">Cardiovascular disease and metabolic syndrome</span><span class="headingEndMark"> — </span>Multiple studies have investigated the relationship between MPHL and cardiovascular disease or risk factors for cardiovascular disease, including studies that have identified elevated rates of cardiovascular disease in patients with vertex hair loss [<a href="#rid56">56,57</a>], vertex and frontal hair loss [<a href="#rid58">58</a>], early-onset hair loss [<a href="#rid59">59</a>], and rapidly progressive hair loss [<a href="#rid59">59</a>]. In addition, increased risks for hypertension [<a href="#rid60">60</a>], excess weight [<a href="#rid61">61</a>], abnormal lipids [<a href="#rid62">62</a>], insulin resistance [<a href="#rid63">63</a>], carotid atheromatosis [<a href="#rid64">64</a>], and death from diabetes or heart disease [<a href="#rid65">65</a>] have been reported in this population.</p><p>Although studies investigating an association between MPHL and the metabolic syndrome have yielded conflicting findings, a meta-analysis of 19 case-control studies (total of 1342 patients with MPHL or female pattern hair loss and 1189 controls) that assessed patients with androgenetic alopecia and age- and sex-matched controls found a higher risk of metabolic syndrome among patients with androgenetic alopecia compared with controls (odds ratio [OR] 3.46, 95% CI 2.38-5.05) [<a href="#rid66">66</a>]. Most patients in the included studies were male. (See  <a class="medical medical_review" href="/z/d/html/1784.html" rel="external">"Metabolic syndrome (insulin resistance syndrome or syndrome X)"</a>.)  </p><p>Distinct guidelines for the detection and prevention of cardiovascular disease and metabolic syndrome in individuals with androgenetic alopecia have not been established. (See  <a class="medical medical_review" href="/z/d/html/1784.html" rel="external">"Metabolic syndrome (insulin resistance syndrome or syndrome X)"</a>.)</p><p class="headingAnchor" id="H2374108577"><span class="h2">Prostate cancer</span><span class="headingEndMark"> — </span>Studies evaluating the relationship between MPHL in males and prostate cancer have yielded varied results [<a href="#rid17">17,67-73</a>]. A systematic review and meta-analysis of seven case-control studies (4078 cases and 4916 controls) that used a standardized tool to classify MPHL found an association between vertex pattern hair loss in MPHL and increased risk for prostate cancer (pooled OR 1.25, 95% CI 1.09-1.44) but did not find an association between any pattern of MPHL and the disease [<a href="#rid74">74</a>]. A subsequent systematic review and meta-analysis that included both case-control and cohort studies yielded similar findings [<a href="#rid75">75</a>].</p><p>An analysis of data from the National Health and Nutrition Examination Survey Epidemiologic Follow-up Study on 4316 males 25 to 74 years of age followed up from between 1971 and 1974 to 2011 found that MPHL was associated with a 56 percent increased risk of death from prostate cancer (hazard ratio [HR] 1.56, 95% CI 1.02-2.37) [<a href="#rid76">76</a>].</p><p>Further confirmation is needed before a recommendation for the use of MPHL in screening decisions for prostate cancer.</p><p class="headingAnchor" id="H1349834880"><span class="h2">Other</span><span class="headingEndMark"> — </span>An 18-year prospective study including over 30,000 male participants in the Health Professionals Follow-up Study found a modest increase in the risk of colon cancer for males with frontal-only baldness and frontal-plus-mild-vertex baldness compared with males without baldness (HR 1.29, 95% CI 1.03-1.62; and HR 1.31, 95% CI 1.01-1.70, respectively) [<a href="#rid77">77</a>]. Additional studies are needed to confirm this association.</p><p>Research continues to show that male badling is associated with an increased risk of skin cancer, including both melanoma and nonmelanoma skin cancers [<a href="#rid78">78,79</a>]. </p><p class="headingAnchor" id="H21714562"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of MPHL is usually straightforward and can be made through obtaining a history and performing an examination of the hair and scalp. Slow, progressive, asymptomatic hair loss with evidence of follicular miniaturization on the temporal, frontal, and/or vertex regions of the scalp supports a diagnosis of MPHL. Other patterns of hair loss or diffuse hair loss should raise suspicion for alternative diagnoses. (See  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Nonscarring alopecia'</a>.)</p><p class="headingAnchor" id="H2138212767"><span class="h2">History</span><span class="headingEndMark"> — </span>The patient history should include an assessment of the progression, distribution, and extent of hair loss, as well as associated symptoms and family history. Patients with MPHL typically describe slow, progressive hair loss without associated symptoms. A family history of similar hair loss is common, but its absence does not rule out androgenetic alopecia.</p><p>Rapid hair loss or hair loss accompanied by itching, burning, or scalp tenderness suggests an alternative or coexisting diagnosis. In particular, rapid hair loss related to telogen effluvium may unmask previously unnoticed MPHL. (See  <a class="medical medical_review" href="/z/d/html/15683.html" rel="external">"Telogen effluvium"</a>.)</p><p>The approach to the patient interview for hair loss is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Patient interview'</a>.)</p><p class="headingAnchor" id="H21714569"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>The physical examination should include careful examination of the scalp and hair. (See  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Physical examination'</a>.)</p><p>Follicular miniaturization in a distribution consistent with MPHL essentially confirms the diagnosis  (<a class="graphic graphic_picture graphicRef83802 graphicRef83804 graphicRef120282 graphicRef83805" href="/z/d/graphic/83802.html" rel="external">picture 1A-D</a>). Examination of the caliber of hair fibers against a paper that is a color that contrasts with the hair facilitates visualization of miniaturized hairs.</p><p>Examination with a dermatoscope is also helpful for identification of miniaturized hairs and diagnosis  (<a class="graphic graphic_picture graphicRef83781" href="/z/d/graphic/83781.html" rel="external">picture 2</a>) [<a href="#rid80">80</a>]. Dermoscopic features of MPHL include hair diameter diversity, perifollicular pigmentation/peripilar signs, and yellow dots  (<a class="graphic graphic_table graphicRef115000" href="/z/d/graphic/115000.html" rel="external">table 1</a>) [<a href="#rid80">80,81</a>]. Focal atrichia (small areas with a complete absence of hair) may also be seen. (See  <a class="medical medical_review" href="/z/d/html/110157.html" rel="external">"Overview of dermoscopy of the hair and scalp"</a>.)</p><p>Patients with clinical findings of MPHL who report rapid hair loss should undergo a hair pull test to assess for coexisting active telogen effluvium. (See  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Hair pull test'</a> and  <a class="medical medical_review" href="/z/d/html/15683.html" rel="external">"Telogen effluvium"</a>.)</p><p class="headingAnchor" id="H21714576"><span class="h2">Scalp biopsy</span><span class="headingEndMark"> — </span>Histopathologic examination is not usually necessary for diagnosis. However, MPHL has distinctive histologic features, and biopsies can be used to confirm the diagnosis in the infrequent cases in which the diagnosis is uncertain [<a href="#rid48">48,82</a>]. (See <a class="local">'Histopathology'</a> above.)</p><p>A 4 mm punch biopsy is the preferred procedure for obtaining a tissue specimen for diagnosis. Many clinicians obtain two biopsies, one for horizontal (transverse) sectioning and one for vertical sectioning. Horizontal sectioning of the tissue specimen allows for visualization of more follicles and tends to yield more useful results than vertical sectioning [<a href="#rid48">48</a>]. Some pathology laboratories will process a single 4 mm punch specimen into vertical and horizontal sections (HoVert technique) [<a href="#rid83">83,84</a>]. (See <a class="local">'Histopathology'</a> above and  <a class="medical medical_review" href="/z/d/html/5577.html" rel="external">"Skin biopsy techniques", section on 'Biopsy techniques'</a>.)</p><p class="headingAnchor" id="H21714583"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Hair loss related to MPHL should be distinguished from other causes of nondiffuse hair loss, such as hairline maturation, alopecia areata, traction alopecia, cicatricial alopecias, and trichotillomania. Given its frequent occurrence, MPHL may also coexist with these and other hair and scalp diseases:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hairline maturation</strong> –<strong> </strong>Slight recession of the hairline is a normal, hormonally mediated occurrence that typically begins in early adulthood. In men, this involves up to two centimeters of posterior recession of the leading edge of the hairline from its childhood position [<a href="#rid85">85</a>]. Minor temporal recession also occurs, further contributing to a change in the shape of the hairline. The limited extent of hairline recession contrasts with the more extensive recession and vertex involvement that occurs in MPHL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alopecia areata</strong> – Alopecia areata is an immune-mediated form of nonscarring hair loss. Alopecia areata most often manifests as sudden hair loss in circular, discrete areas but may also present with larger patches of alopecia or loss of all scalp hair  (<a class="graphic graphic_picture graphicRef76247" href="/z/d/graphic/76247.html" rel="external">picture 4</a>). In particular, the rare sisaipho (ophiasis inversus) pattern, which involves loss of hair on the frontal, temporal, and parietal scalp, may be mistaken for MPHL  (<a class="graphic graphic_picture graphicRef110290" href="/z/d/graphic/110290.html" rel="external">picture 5</a>). In contrast to the slow, progressive course of MPHL, hair loss in alopecia areata tends to be rapid. A scalp biopsy is useful for distinguishing challenging cases. (See  <a class="medical medical_review" href="/z/d/html/3320.html" rel="external">"Alopecia areata: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Traction alopecia</strong> – Traction alopecia is a type of hair loss that results from prolonged or repetitive tension on hair. The location of hair loss correlates with the site of traction. The frontal and temporal scalp are the most common affected areas  (<a class="graphic graphic_picture graphicRef60331" href="/z/d/graphic/60331.html" rel="external">picture 6</a>). A history of a traction-inducing hairstyle and hair loss in the correlating distribution supports the diagnosis. If the diagnosis remains uncertain, a biopsy can be helpful. (See  <a class="medical medical_review" href="/z/d/html/99226.html" rel="external">"Traction alopecia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cicatricial (scarring) alopecias</strong> – Patches of scarring hair loss or frontal hairline recession from cicatricial alopecias may be confused with MPHL, particularly when clinical signs of inflammation are minimal or resolved  (<a class="graphic graphic_picture graphicRef90010 graphicRef90009 graphicRef91652" href="/z/d/graphic/90010.html" rel="external">picture 7A-C</a>). However, unlike MPHL, close examination of the involved scalp will reveal findings consistent with scarring (absence of follicular ostia and vellus hairs). In addition, a history of inflammatory signs or symptoms (eg, pruritus, pain, inflamed papules, pustules) in the affected area is often present in cicatricial alopecias. When necessary, a scalp biopsy can distinguish MPHL from cicatricial alopecia. (See  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Cicatricial alopecia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trichotillomania</strong> – Trichotillomania is a psychiatric disorder characterized by recurrent hair pulling. Patients often present with bizarrely shaped patches of alopecia and hair shafts of different lengths due to multiple episodes of hair pulling. The diagnosis usually can be made based upon the patient history. A scalp biopsy can help to confirm the diagnosis in challenging cases. (See  <a class="medical medical_review" href="/z/d/html/13698.html" rel="external">"Skin picking (excoriation) disorder and related disorders", section on 'Trichotillomania'</a>.)</p><p></p><p class="headingAnchor" id="H268668558"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117218.html" rel="external">"Society guideline links: Alopecia"</a>.)</p><p class="headingAnchor" id="H21714626"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15436.html" rel="external">"Patient education: Hair loss (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/7640.html" rel="external">"Patient education: Androgenetic alopecia in men and women (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H21714633"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Male pattern hair loss (MPHL) is a common condition in postpubertal males that is characterized by the loss of terminal hairs in select areas on the scalp. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Hormonal, genetic, and other factors contribute to the development of MPHL. The effects of dihydrotestosterone on susceptible follicles contributes to follicular miniaturization, which manifests clinically as the replacement of terminal hairs by short, thin (vellus) hairs. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The appearance of MPHL varies among individuals. The temporal, anterior, mid scalp, and/or vertex areas of the scalp are typically affected  (<a class="graphic graphic_picture graphicRef83802 graphicRef83804 graphicRef120282 graphicRef83805" href="/z/d/graphic/83802.html" rel="external">picture 1A-D</a>). The occipital scalp is usually spared. The loss of terminal hairs slowly progresses over the course of years. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of MPHL is usually made clinically and is based upon the detection of slow, progressive hair loss and follicular miniaturization in a distribution consistent with androgenetic alopecia. For the infrequent cases in which the diagnosis is uncertain, a biopsy can be used to confirm the diagnosis. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated disorders</strong> – Some individuals with MPHL may experience negative psychosocial effects. MPHL has also been associated with other disorders, such as cardiovascular disease and prostate cancer. (See <a class="local">'Associated disorders'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Paik JH, Yoon JB, Sim WY, et al. The prevalence and types of androgenetic alopecia in Korean men and women. Br J Dermatol 2001; 145:95.</a></li><li><a class="nounderline abstract_t">Severi G, Sinclair R, Hopper JL, et al. Androgenetic alopecia in men aged 40-69 years: prevalence and risk factors. Br J Dermatol 2003; 149:1207.</a></li><li><a class="nounderline abstract_t">Pathomvanich D, Pongratananukul S, Thienthaworn P, Manoshai S. A random study of Asian male androgenetic alopecia in Bangkok, Thailand. Dermatol Surg 2002; 28:804.</a></li><li><a class="nounderline abstract_t">Su LH, Chen TH. Association of androgenetic alopecia with smoking and its prevalence among Asian men: a community-based survey. Arch Dermatol 2007; 143:1401.</a></li><li><a class="nounderline abstract_t">Gan DC, Sinclair RD. Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc 2005; 10:184.</a></li><li><a class="nounderline abstract_t">Rhodes T, Girman CJ, Savin RC, et al. Prevalence of male pattern hair loss in 18-49 year old men. Dermatol Surg 1998; 24:1330.</a></li><li><a class="nounderline abstract_t">Krupa Shankar D, Chakravarthi M, Shilpakar R. Male androgenetic alopecia: population-based study in 1,005 subjects. Int J Trichology 2009; 1:131.</a></li><li><a class="nounderline abstract_t">Özcan D. Pediatric androgenetic alopecia: a retrospective review of clinical characteristics, hormonal assays and metabolic syndrome risk factors in 23 patients. An Bras Dermatol 2022; 97:166.</a></li><li><a class="nounderline abstract_t">Trüeb RM, Casañas-Quintana E, Régnier A, Caballero-Uribe N. Prepubertal pattern hair loss. Clin Exp Dermatol 2022; 47:173.</a></li><li><a class="nounderline abstract_t">Tosti A, Iorizzo M, Piraccini BM. Androgenetic alopecia in children: report of 20 cases. Br J Dermatol 2005; 152:556.</a></li><li><a class="nounderline abstract_t">Patterson MN, McPhaul MJ, Hughes IA. Androgen insensitivity syndrome. Baillieres Clin Endocrinol Metab 1994; 8:379.</a></li><li><a class="nounderline abstract_t">Kaufman KD. Androgens and alopecia. Mol Cell Endocrinol 2002; 198:89.</a></li><li><a class="nounderline abstract_t">Imperato-McGinley J, Zhu YS. Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency. Mol Cell Endocrinol 2002; 198:51.</a></li><li><a class="nounderline abstract_t">Price VH. Treatment of hair loss. N Engl J Med 1999; 341:964.</a></li><li><a class="nounderline abstract_t">Vierhapper H, Nowotny P, Maier H, Waldhäusl W. Production rates of dihydrotestosterone in healthy men and women and in men with male pattern baldness: determination by stable isotope/dilution and mass spectrometry. J Clin Endocrinol Metab 2001; 86:5762.</a></li><li><a class="nounderline abstract_t">Schmidt JB, Lindmaier A, Spona J. Hormonal parameters in androgenetic hair loss in the male. Dermatologica 1991; 182:214.</a></li><li><a class="nounderline abstract_t">Demark-Wahnefried W, Lesko SM, Conaway MR, et al. Serum androgens: associations with prostate cancer risk and hair patterning. J Androl 1997; 18:495.</a></li><li><a class="nounderline abstract_t">Cipriani R, Ruzza G, Foresta C, et al. Sex hormone-binding globulin and saliva testosterone levels in men with androgenetic alopecia. Br J Dermatol 1983; 109:249.</a></li><li><a class="nounderline abstract_t">Cocchetti C, Castellini G, Maggi M, et al. Effects of hormonal treatment on dermatological outcome in transgender people: a multicentric prospective study (ENIGI). J Endocrinol Invest 2023; 46:779.</a></li><li><a class="nounderline abstract_t">Heilmann-Heimbach S, Hochfeld LM, Paus R, Nöthen MM. Hunting the genes in male-pattern alopecia: how important are they, how close are we and what will they tell us? Exp Dermatol 2016; 25:251.</a></li><li><a class="nounderline abstract_t">Ellis JA, Stebbing M, Harrap SB. Genetic analysis of male pattern baldness and the 5alpha-reductase genes. J Invest Dermatol 1998; 110:849.</a></li><li><a class="nounderline abstract_t">Birch MP, Messenger AG. Genetic factors predispose to balding and non-balding in men. Eur J Dermatol 2001; 11:309.</a></li><li><a class="nounderline abstract_t">Nyholt DR, Gillespie NA, Heath AC, Martin NG. Genetic basis of male pattern baldness. J Invest Dermatol 2003; 121:1561.</a></li><li><a class="nounderline abstract_t">Heilmann-Heimbach S, Herold C, Hochfeld LM, et al. Meta-analysis identifies novel risk loci and yields systematic insights into the biology of male-pattern baldness. Nat Commun 2017; 8:14694.</a></li><li><a class="nounderline abstract_t">Hagenaars SP, Hill WD, Harris SE, et al. Genetic prediction of male pattern baldness. PLoS Genet 2017; 13:e1006594.</a></li><li><a class="nounderline abstract_t">Hillmer AM, Hanneken S, Ritzmann S, et al. Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. Am J Hum Genet 2005; 77:140.</a></li><li><a class="nounderline abstract_t">Hillmer AM, Brockschmidt FF, Hanneken S, et al. Susceptibility variants for male-pattern baldness on chromosome 20p11. Nat Genet 2008; 40:1279.</a></li><li><a class="nounderline abstract_t">Richards JB, Yuan X, Geller F, et al. Male-pattern baldness susceptibility locus at 20p11. Nat Genet 2008; 40:1282.</a></li><li><a class="nounderline abstract_t">Brockschmidt FF, Heilmann S, Ellis JA, et al. Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness. Br J Dermatol 2011; 165:1293.</a></li><li><a class="nounderline abstract_t">Hillmer AM, Flaquer A, Hanneken S, et al. Genome-wide scan and fine-mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26. Am J Hum Genet 2008; 82:737.</a></li><li><a class="nounderline abstract_t">Henne SK, Aldisi R, Sivalingam S, et al. Analysis of 72,469 UK Biobank exomes links rare variants to male-pattern hair loss. Nat Commun 2023; 14:5492.</a></li><li><a class="nounderline abstract_t">Ellis JA, Sinclair R, Harrap SB. Androgenetic alopecia: pathogenesis and potential for therapy. Expert Rev Mol Med 2002; 4:1.</a></li><li><a class="nounderline abstract_t">Hamada K, Randall VA. Inhibitory autocrine factors produced by the mesenchyme-derived hair follicle dermal papilla may be a key to male pattern baldness. Br J Dermatol 2006; 154:609.</a></li><li><a class="nounderline abstract_t">Sawaya ME. Purification of androgen receptors in human sebocytes and hair. J Invest Dermatol 1992; 98:92S.</a></li><li><a class="nounderline abstract_t">Sawaya ME, Shalita AR. Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne. J Cutan Med Surg 1998; 3:9.</a></li><li><a class="nounderline abstract_t">Sawaya ME, Price VH. Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 1997; 109:296.</a></li><li><a class="nounderline abstract_t">Sawaya ME. Steroid chemistry and hormone controls during the hair follicle cycle. Ann N Y Acad Sci 1991; 642:376.</a></li><li><a class="nounderline abstract_t">Hochfeld LM, Keller A, Anhalt T, et al. Insights into Male Androgenetic Alopecia: Differential Gene Expression Profiling of Plucked Hair Follicles and Integration with Genetic Data. J Invest Dermatol 2019; 139:235.</a></li><li><a class="nounderline abstract_t">Premanand A, Reena Rajkumari B. Androgen modulation of Wnt/β-catenin signaling in androgenetic alopecia. Arch Dermatol Res 2018; 310:391.</a></li><li><a class="nounderline abstract_t">Nieves A, Garza LA. Does prostaglandin D2 hold the cure to male pattern baldness? Exp Dermatol 2014; 23:224.</a></li><li><a class="nounderline abstract_t">Keaney T. Emerging Therapies for Androgenetic Alopecia. J Drugs Dermatol 2015; 14:1036.</a></li><li><a class="nounderline abstract_t">Vañó-Galván S, Camacho F. New Treatments for Hair Loss. Actas Dermosifiliogr 2017; 108:221.</a></li><li><a class="nounderline abstract_t">Gupta M, Mysore V. Classifications of Patterned Hair Loss: A Review. J Cutan Aesthet Surg 2016; 9:3.</a></li><li><a class="nounderline abstract_t">Norwood OT. Male pattern baldness: classification and incidence. South Med J 1975; 68:1359.</a></li><li><a class="nounderline abstract_t">Norwood OT. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg 2001; 27:53.</a></li><li class="breakAll">Whiting DA, Reisenauer AK, Parker D, et al. Disorders of cutaneous appendages. In: Dermatopathology, 3rd ed, Barnhill RL, Crowson AN, Magro CM, et al. (Eds), McGraw-Hill, 2010. p.215.</li><li><a class="nounderline abstract_t">Horenstein MG, Jacob JS. Follicular streamers (stelae) in scarring and non-scarring alopecia. J Cutan Pathol 2008; 35:1115.</a></li><li><a class="nounderline abstract_t">Whiting DA. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol 1993; 28:755.</a></li><li><a class="nounderline abstract_t">Headington JT. Transverse microscopic anatomy of the human scalp. A basis for a morphometric approach to disorders of the hair follicle. Arch Dermatol 1984; 120:449.</a></li><li><a class="nounderline abstract_t">Plante J, Valdebran M, Forcucci J, et al. Perifollicular inflammation and follicular spongiosis in androgenetic alopecia. J Am Acad Dermatol 2022; 86:437.</a></li><li><a class="nounderline abstract_t">Nirmal B, Somiah S, Sacchidanand SA, et al. Evaluation of Perifollicular Inflammation of Donor Area during Hair Transplantation in Androgenetic Alopecia and its Comparison with Controls. Int J Trichology 2013; 5:73.</a></li><li><a class="nounderline abstract_t">Ramos PM, Brianezi G, Martins AC, et al. Apoptosis in follicles of individuals with female pattern hair loss is associated with perifollicular microinflammation. Int J Cosmet Sci 2016; 38:651.</a></li><li><a class="nounderline abstract_t">El-Domyati M, Attia S, Saleh F, Abdel-Wahab H. Androgenetic alopecia in males: a histopathological and ultrastructural study. J Cosmet Dermatol 2009; 8:83.</a></li><li><a class="nounderline abstract_t">Yoo HG, Kim JS, Lee SR, et al. Perifollicular fibrosis: pathogenetic role in androgenetic alopecia. Biol Pharm Bull 2006; 29:1246.</a></li><li><a class="nounderline abstract_t">Cash TF. The psychosocial consequences of androgenetic alopecia: a review of the research literature. Br J Dermatol 1999; 141:398.</a></li><li><a class="nounderline abstract_t">Lesko SM, Rosenberg L, Shapiro S. A case-control study of baldness in relation to myocardial infarction in men. JAMA 1993; 269:998.</a></li><li><a class="nounderline abstract_t">Lotufo PA, Chae CU, Ajani UA, et al. Male pattern baldness and coronary heart disease: the Physicians' Health Study. Arch Intern Med 2000; 160:165.</a></li><li><a class="nounderline abstract_t">Schnohr P, Lange P, Nyboe J, et al. Gray hair, baldness, and wrinkles in relation to myocardial infarction: the Copenhagen City Heart Study. Am Heart J 1995; 130:1003.</a></li><li><a class="nounderline abstract_t">Herrera CR, D'Agostino RB, Gerstman BB, et al. Baldness and coronary heart disease rates in men from the Framingham Study. Am J Epidemiol 1995; 142:828.</a></li><li><a class="nounderline abstract_t">Ahouansou S, Le Toumelin P, Crickx B, Descamps V. Association of androgenetic alopecia and hypertension. Eur J Dermatol 2007; 17:220.</a></li><li><a class="nounderline abstract_t">Hirsso P, Rajala U, Hiltunen L, et al. Obesity and low-grade inflammation among young Finnish men with early-onset alopecia. Dermatology 2007; 214:125.</a></li><li><a class="nounderline abstract_t">Sasmaz S, Senol M, Ozcan A, et al. The risk of coronary heart disease in men with androgenetic alopecia. J Eur Acad Dermatol Venereol 1999; 12:123.</a></li><li><a class="nounderline abstract_t">Matilainen V, Koskela P, Keinänen-Kiukaanniemi S. Early androgenetic alopecia as a marker of insulin resistance. Lancet 2000; 356:1165.</a></li><li><a class="nounderline abstract_t">Arias-Santiago S, Gutiérrez-Salmerón MT, Castellote-Caballero L, et al. Androgenetic alopecia and cardiovascular risk factors in men and women: a comparative study. J Am Acad Dermatol 2010; 63:420.</a></li><li><a class="nounderline abstract_t">Su LH, Chen LS, Lin SC, Chen HH. Association of androgenetic alopecia with mortality from diabetes mellitus and heart disease. JAMA Dermatol 2013; 149:601.</a></li><li><a class="nounderline abstract_t">Qiu Y, Zhou X, Fu S, et al. Systematic Review and Meta-analysis of the Association Between Metabolic Syndrome and Androgenetic Alopecia. Acta Derm Venereol 2022; 102:adv00645.</a></li><li><a class="nounderline abstract_t">Hawk E, Breslow RA, Graubard BI. Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 2000; 9:523.</a></li><li><a class="nounderline abstract_t">Yassa M, Saliou M, De Rycke Y, et al. Male pattern baldness and the risk of prostate cancer. Ann Oncol 2011; 22:1824.</a></li><li><a class="nounderline abstract_t">Giles GG, Severi G, Sinclair R, et al. Androgenetic alopecia and prostate cancer: findings from an Australian case-control study. Cancer Epidemiol Biomarkers Prev 2002; 11:549.</a></li><li><a class="nounderline abstract_t">Hsieh CC, Thanos A, Mitropoulos D, et al. Risk factors for prostate cancer: a case-control study in Greece. Int J Cancer 1999; 80:699.</a></li><li><a class="nounderline abstract_t">Zhou CK, Littman AJ, Levine PH, et al. Male pattern baldness in relation to prostate cancer risks: an analysis in the VITamins and lifestyle (VITAL) cohort study. Prostate 2015; 75:415.</a></li><li><a class="nounderline abstract_t">Cremers RG, Aben KK, Vermeulen SH, et al. Androgenic alopecia is not useful as an indicator of men at high risk of prostate cancer. Eur J Cancer 2010; 46:3294.</a></li><li><a class="nounderline abstract_t">Wright JL, Page ST, Lin DW, Stanford JL. Male pattern baldness and prostate cancer risk in a population-based case-control study. Cancer Epidemiol 2010; 34:131.</a></li><li><a class="nounderline abstract_t">Amoretti A, Laydner H, Bergfeld W. Androgenetic alopecia and risk of prostate cancer: a systematic review and meta-analysis. J Am Acad Dermatol 2013; 68:937.</a></li><li><a class="nounderline abstract_t">He H, Xie B, Xie L. Male pattern baldness and incidence of prostate cancer: A systematic review and meta-analysis. Medicine (Baltimore) 2018; 97:e11379.</a></li><li><a class="nounderline abstract_t">Zhou CK, Levine PH, Cleary SD, et al. Male Pattern Baldness in Relation to Prostate Cancer-Specific Mortality: A Prospective Analysis in the NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 2016; 183:210.</a></li><li><a class="nounderline abstract_t">Keum N, Cao Y, Lee DH, et al. Male pattern baldness and risk of colorectal neoplasia. Br J Cancer 2016; 114:110.</a></li><li><a class="nounderline abstract_t">Ong JS, Seviiri M, Dusingize JC, et al. Uncovering the complex relationship between balding, testosterone and skin cancers in men. Nat Commun 2023; 14:5962.</a></li><li><a class="nounderline abstract_t">Li WQ, Cho E, Han J, et al. Male pattern baldness and risk of incident skin cancer in a cohort of men. Int J Cancer 2016; 139:2671.</a></li><li><a class="nounderline abstract_t">Inui S. Trichoscopy for common hair loss diseases: algorithmic method for diagnosis. J Dermatol 2011; 38:71.</a></li><li><a class="nounderline abstract_t">Mubki T, Rudnicka L, Olszewska M, Shapiro J. Evaluation and diagnosis of the hair loss patient: part II. Trichoscopic and laboratory evaluations. J Am Acad Dermatol 2014; 71:431.e1.</a></li><li><a class="nounderline abstract_t">Whiting DA. Possible mechanisms of miniaturization during androgenetic alopecia or pattern hair loss. J Am Acad Dermatol 2001; 45:S81.</a></li><li><a class="nounderline abstract_t">Kolivras A, Thompson C. Primary scalp alopecia: new histopathological tools, new concepts and a practical guide to diagnosis. J Cutan Pathol 2017; 44:53.</a></li><li><a class="nounderline abstract_t">Nguyen JV, Hudacek K, Whitten JA, et al. The HoVert technique: a novel method for the sectioning of alopecia biopsies. J Cutan Pathol 2011; 38:401.</a></li><li><a class="nounderline abstract_t">Rassman WR, Pak JP, Kim J. Phenotype of normal hairline maturation. Facial Plast Surg Clin North Am 2013; 21:317.</a></li></ol></div><div id="topicVersionRevision">Topic 83783 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11453914" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The prevalence and types of androgenetic alopecia in Korean men and women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14674898" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Androgenetic alopecia in men aged 40-69 years: prevalence and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12269873" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A random study of Asian male androgenetic alopecia in Bangkok, Thailand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18025364" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Association of androgenetic alopecia with smoking and its prevalence among Asian men: a community-based survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16382660" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prevalence of male and female pattern hair loss in Maryborough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9865198" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence of male pattern hair loss in 18-49 year old men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20927235" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Male androgenetic alopecia: population-based study in 1,005 subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35033390" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pediatric androgenetic alopecia: a retrospective review of clinical characteristics, hormonal assays and metabolic syndrome risk factors in 23 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34347893" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prepubertal pattern hair loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15787828" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Androgenetic alopecia in children: report of 20 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8092978" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Androgen insensitivity syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12573818" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Androgens and alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12573814" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10498493" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment of hair loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11739436" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Production rates of dihydrotestosterone in healthy men and women and in men with male pattern baldness: determination by stable isotope/dilution and mass spectrometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1832108" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hormonal parameters in androgenetic hair loss in the male.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9349747" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Serum androgens: associations with prostate cancer risk and hair patterning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6684473" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Sex hormone-binding globulin and saliva testosterone levels in men with androgenetic alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36348253" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effects of hormonal treatment on dermatological outcome in transgender people: a multicentric prospective study (ENIGI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26843402" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hunting the genes in male-pattern alopecia: how important are they, how close are we and what will they tell us?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9620288" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Genetic analysis of male pattern baldness and the 5alpha-reductase genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11399536" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Genetic factors predispose to balding and non-balding in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14675213" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Genetic basis of male pattern baldness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28272467" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Meta-analysis identifies novel risk loci and yields systematic insights into the biology of male-pattern baldness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28196072" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Genetic prediction of male pattern baldness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15902657" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18849994" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Susceptibility variants for male-pattern baldness on chromosome 20p11.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18849991" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Male-pattern baldness susceptibility locus at 20p11.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22032556" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18304493" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Genome-wide scan and fine-mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37737258" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Analysis of 72,469 UK Biobank exomes links rare variants to male-pattern hair loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14585162" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Androgenetic alopecia: pathogenesis and potential for therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16536801" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Inhibitory autocrine factors produced by the mesenchyme-derived hair follicle dermal papilla may be a key to male pattern baldness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1588131" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Purification of androgen receptors in human sebocytes and hair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9677254" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9284093" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1809093" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Steroid chemistry and hormone controls during the hair follicle cycle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30009830" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Insights into Male Androgenetic Alopecia: Differential Gene Expression Profiling of Plucked Hair Follicles and Integration with Genetic Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29549490" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Androgen modulation of Wnt/β-catenin signaling in androgenetic alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24521203" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Does prostaglandin D2 hold the cure to male pattern baldness?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26355625" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Emerging Therapies for Androgenetic Alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28061966" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : New Treatments for Hair Loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27081243" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Classifications of Patterned Hair Loss: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1188424" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Male pattern baldness: classification and incidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11231244" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Incidence of female androgenetic alopecia (female pattern alopecia).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11231244" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Incidence of female androgenetic alopecia (female pattern alopecia).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18616766" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Follicular streamers (stelae) in scarring and non-scarring alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8496421" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6703750" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Transverse microscopic anatomy of the human scalp. A basis for a morphometric approach to disorders of the hair follicle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34587554" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Perifollicular inflammation and follicular spongiosis in androgenetic alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24403768" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Evaluation of Perifollicular Inflammation of Donor Area during Hair Transplantation in Androgenetic Alopecia and its Comparison with Controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27163333" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Apoptosis in follicles of individuals with female pattern hair loss is associated with perifollicular microinflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19527330" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Androgenetic alopecia in males: a histopathological and ultrastructural study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16755026" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Perifollicular fibrosis: pathogenetic role in androgenetic alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10583042" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The psychosocial consequences of androgenetic alopecia: a review of the research literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8429606" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A case-control study of baldness in relation to myocardial infarction in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10647754" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Male pattern baldness and coronary heart disease: the Physicians' Health Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7484729" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Gray hair, baldness, and wrinkles in relation to myocardial infarction: the Copenhagen City Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7572959" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Baldness and coronary heart disease rates in men from the Framingham Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17478384" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Association of androgenetic alopecia and hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17341860" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Obesity and low-grade inflammation among young Finnish men with early-onset alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10343940" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The risk of coronary heart disease in men with androgenetic alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11030300" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Early androgenetic alopecia as a marker of insulin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20619491" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Androgenetic alopecia and cardiovascular risk factors in men and women: a comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23677087" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Association of androgenetic alopecia with mortality from diabetes mellitus and heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34935992" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Systematic Review and Meta-analysis of the Association Between Metabolic Syndrome and Androgenetic Alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10815699" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21324955" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Male pattern baldness and the risk of prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12050096" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Androgenetic alopecia and prostate cancer: findings from an Australian case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10048970" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Risk factors for prostate cancer: a case-control study in Greece.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25492530" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Male pattern baldness in relation to prostate cancer risks: an analysis in the VITamins and lifestyle (VITAL) cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20561779" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Androgenic alopecia is not useful as an indicator of men at high risk of prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20206591" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Male pattern baldness and prostate cancer risk in a population-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23395589" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Androgenetic alopecia and risk of prostate cancer: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29995779" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Male pattern baldness and incidence of prostate cancer: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26764224" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Male Pattern Baldness in Relation to Prostate Cancer-Specific Mortality: A Prospective Analysis in the NHANES I Epidemiologic Follow-up Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26757425" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Male pattern baldness and risk of colorectal neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37789011" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Uncovering the complex relationship between balding, testosterone and skin cancers in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27542665" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Male pattern baldness and risk of incident skin cancer in a cohort of men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21175759" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Trichoscopy for common hair loss diseases: algorithmic method for diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25128119" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Evaluation and diagnosis of the hair loss patient: part II. Trichoscopic and laboratory evaluations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11511857" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Possible mechanisms of miniaturization during androgenetic alopecia or pattern hair loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27682637" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Primary scalp alopecia: new histopathological tools, new concepts and a practical guide to diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21251040" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The HoVert technique: a novel method for the sectioning of alopecia biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24017973" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Phenotype of normal hairline maturation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
